Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
News
Healthcare Conference Updates: AUXL, CTIC, CYTX, KERX
Below are some updates and developments from the past week.
[OneMedForum] NuVue Therapeutics’ Multi-Step Approach to Cancer Therapy
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
[OneMedForum] OrSense: Non-Invasive Blood Monitoring Solutions
Israel-based OrSense is attempting to increase patient compliance with a non-invasive continuous glucose monitor based on optical technology.
[OneMedForum] Jaleva Pharmaceuticals
One company presenting at the conference is San Diego-based Jaleva Pharmaceuticals, which has developed a resin-based delivery vehicle for topical medications.
Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
EyeGate Raises $22.6M In Venture Funding
The money will be used to further the company’s development of EGP-437 to treat dry eye syndrome.
Enzon and Sopherion Make Breast Cancer Progress
Two biopharmaceutical companies took a step forward this week with their pipelines for advanced breast cancer.
As Seasonal Flu Ramps Up, NexBio Begins Phase II Trial for DAS181
DAS181 is formulated to prevent the influenza virus from entering cells in the respiratory tract.